Genmab (Nasdaq:GMAB) - Cotización, noticias y análisis

Resumen de acción GMAB

Genmab A/S desarrolla terapias de anticuerpos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca.

Acerca de la empresa

GMAB fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 68.3% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 21.65%

Los beneficios aumentaron un 3.5% el pasado año

Análisis de riesgos

No se han detectado riesgos en GMAB a partir de nuestros controles de riesgos.

Competidores de Genmab A/S

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Neurocrine Biosciences

NasdaqGS:NBIX

US$13.8b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$15.4b

United Therapeutics

NasdaqGS:UTHR

US$11.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Price	kr.28.84
52 Week High	kr.42.72
52 Week Low	kr.26.32
Beta	0.79
1 Month Change	-1.44%
3 Month Change	4.91%
1 Year Change	-30.82%
3 Year Change	-22.22%
5 Year Change	67.63%
Change since IPO	704.91%

Noticias y actualizaciones recientes

Genmab: A Complicated Tale

May 01

Genmab Acquires A Missing Piece For Its Pipeline

Apr 16

Recent updates

Rentabilidad de los accionistas

	GMAB	US Biotechs	Mercado US
7D	-3.0%	-1.3%	1.6%
1Y	-30.8%	3.0%	26.3%

Rentabilidad vs. Industria: GMAB obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: GMAB obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is GMAB's price volatile compared to industry and market?
GMAB volatility
GMAB Average Weekly Movement	5.1%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: GMAB no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de GMAB (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	2,286	Jan G.J. de Winkel	www.genmab.com

Genmab A/S desarrolla anticuerpos terapéuticos para el tratamiento del cáncer y otras enfermedades, principalmente en Dinamarca. La empresa comercializa DARZALEX, un anticuerpo monoclonal humano para el tratamiento de pacientes con mieloma múltiple (MM); teprotumumab para el tratamiento de la enfermedad ocular tiroidea; y Amivantamab para el cáncer gástrico o esofágico avanzado o metastásico y el CPNM. Sus productos incluyen daratumumab para tratar MM, cánceres de la sangre no MM y amiloidosis AL; GEN1047; tisotumab vedotin para tratar cánceres de cuello uterino, ovario y sólidos; DuoBody-PD-L1x4-1BB, y DuoBody-CD40x4-1BB para tratar tumores sólidos; Epcoritamab para el linfoma difuso de células B grandes y la leucemia linfocítica crónica en recaída o refractarios; y HexaBody-CD38 y GEN3017 para el tratamiento de neoplasias hematológicas.

Resumen de fundamentos de Genmab A/S

¿Cómo se comparan los beneficios e ingresos de Genmab con su capitalización de mercado?
Estadísticas fundamentales de GMAB
Capitalización bursátil	US$18.68b
Beneficios(TTM)	US$789.38m
Ingresos (TTM)	US$2.57b

23.7x

Ratio precio-beneficio (PE)

7.3x

Ratio precio-ventas (PS)

¿Está GMAB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de GMAB
Ingresos	kr.17.78b
Coste de los ingresos	kr.411.00m
Beneficio bruto	kr.17.37b
Otros gastos	kr.11.91b
Beneficios	kr.5.47b

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 01, 2024

Beneficios por acción (BPA)	84.64
Margen bruto	97.69%
Margen de beneficio neto	30.74%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado GMAB a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción GMAB

Recompensas

Análisis de riesgos

Competidores de Genmab A/S

NasdaqGS:HZNP

US$26.6b

NasdaqGS:NBIX

US$13.8b

NasdaqGS:BMRN

US$15.4b

NasdaqGS:UTHR

US$11.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Recent updates

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab: A Royalty Powerhouse With A Strong Pipeline

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab: Looking For Growth At A Reasonable Price

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab: A Biotech Company On The Rise

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab A/S Provides Earnings Guidance for the Year 2022

Genmab: Ready For More Growth In 2022

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

U.S. Food and Drug Administration Grants Approval to TIVDAK

Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer

Genmab A/S Announces the Lancet Published the Results of FIH Trial

Genmab: Monoclonal Antibody Experts, Low Risk Business Model

Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021

Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis